ArticleACS nano2026
Ligand-Engineered Methylammonium Lead Bromide Nanoplatelets: Single-Photon Emission and Strong Light-Matter Coupling.
Article in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polarized luminescence in halide perovskite nanocrystals: from fundamental microscopic mechanisms to advanced optoelectronic applications.Frontiers in chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lead halide perovskite nanoplatelets (LHP NPLs) are of immense interest in the materials science and optoelectronics communities owing to their strong quantum confinement leading to narrow emission peaks, thickness-dependent tunable photoluminescence, and large exciton binding energies. Thus far, their further development and photophysical investigations at ensemble and single-particle levels have been impeded by suboptimal ligand passivation, inferior environmental and colloidal stability compared to their 3D nanocrystal counterparts, and limited compositional diversity. Here, we report highly monodisperse methylammonium lead bromide (MAPbBr
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.